RxBNLucentis
ranibizumab
1 reference · 4 interchangeable
Reference Product
Lucentis
ranibizumab
351(a) Reference Product (Approval Date 13-Oct-2016)
ApplicantGenentech, Inc.
BLA125156
RouteIntravitreal
Presentation
Pre-Filled Syringe
Lucentis
ranibizumab
351(a) Reference Product (Approval Date 13-Oct-2016)
ApplicantGenentech, Inc.
BLA125156
·RouteIntravitreal
Presentation
Pre-Filled Syringe
Interchangeable Biosimilars
Byooviz
ranibizumab-nuna
351(k) Interchangeable Biosimilar (Interchangeable Approval Date 3-Oct-2023)
ApplicantSamsung Bioepis Co., Ltd.
BLA761202
RouteIntravitreal
Presentation
Single-Dose Vial
Byooviz
ranibizumab-nuna
351(k) Interchangeable Biosimilar (Interchangeable Approval Date 3-Oct-2023)
ApplicantSamsung Bioepis Co., Ltd.
BLA761202
·RouteIntravitreal
Presentation
Single-Dose Vial
Cimerli
ranibizumab-eqrn
351(k) Interchangeable Biosimilar (Interchangeable Approval Date 2-Aug-2022)
ApplicantSandoz Inc.
BLA761165
RouteIntravitreal
Presentation
Single-Dose Vial
Cimerli
ranibizumab-eqrn
351(k) Interchangeable Biosimilar (Interchangeable Approval Date 2-Aug-2022)
ApplicantSandoz Inc.
BLA761165
·RouteIntravitreal
Presentation
Single-Dose Vial
Nufymco
ranibizumab-leyk
351(k) Interchangeable Biosimilar (Interchangeable Approval Date 18-Dec-2025)
ApplicantZydus Lifesciences Global FZE
BLA761473
RouteIntravitreal
Presentation
Single-Dose Vial
Nufymco
ranibizumab-leyk
351(k) Interchangeable Biosimilar (Interchangeable Approval Date 18-Dec-2025)
ApplicantZydus Lifesciences Global FZE
BLA761473
·RouteIntravitreal
Presentation
Single-Dose Vial
Ranluspec
ranibizumab-hkdz
351(k) Interchangeable Biosimilar (Interchangeable Approval Date 2-Jun-2026)
ApplicantLupin Limited (Biotech Division)
BLA761480
RouteIntravitreal
Presentation
Pre-Filled SyringeSingle-Dose Vial
Ranluspec
ranibizumab-hkdz
351(k) Interchangeable Biosimilar (Interchangeable Approval Date 2-Jun-2026)
ApplicantLupin Limited (Biotech Division)
BLA761480
·RouteIntravitreal
Presentation
Pre-Filled SyringeSingle-Dose Vial
Biosimilars (not interchangeable)
No non-interchangeable biosimilars in this group.